ERBB2 and breast carcinoma: HER-2+ breast cancer patients who were treated with a combination of systemic therapy and anti-HER-2 therapy (trastuzumab) had longer overall survival (OS) and progression-free survival (PFS) than those who received only systemic therapy [31].